-
BioScale Announces First Installation Of The ViBE Protein Analysis Workstation
8/24/2010
BioScale Inc., an innovative life science company that develops, manufactures and promotes novel analytical tools enabling advancements in protein research, recently announced the first shipment and installation of the ViBE™ Protein Analysis Workstation at a major Massachusetts-based pharmaceutical company
-
Simulations Plus Releases GastroPlus Version 7.0
8/24/2010
Simulations Plus, Inc., a leading provider of simulation and modeling software for pharmaceutical discovery and development, has announced the launch of Version 7.0 of GastroPlus, the industry's gold standard software for the simulation of drug absorption, pharmacokinetics, and pharmacodynamics
-
Instem Announces Global Partnership Agreement With SAS In Life Sciences
8/19/2010
Instem, a leading provider of early drug development software solutions, announced recently it has signed a global partnership agreement with SAS, the leader in business analytics software and services. The partnering arrangement enables Instem to more cost effectively license its clients directly for SAS technology embedded within its Provantis preclinical software suite
-
Antibody Licence Agreement With Cancer Research Technology
8/11/2010
Scancell Holdings Plc, the developer of therapeutic cancer vaccines, and Cancer Research Technology Ltd (‘CRT') - Cancer Research UK's commercialisation and development arm recently announce that they have signed an agreement under which Scancell has been granted a licence to use a human antibody known as 105AD7.
-
New Quality Management Software Created Specifically For Small To Medium Size Companies
8/9/2010
TrackWise SelectStart is a purpose-built quality management solution created specifically for small to medium size companies across different segments of life science industries.
-
Generex Biotechnology Creates Scientific Advisory Board To Further The Progression Of Its Drug Development Programs
8/5/2010
Generex Biotechnology Corporation (GNBT 0.40, +0.02, +6.10%)the leader in drug delivery for metabolic diseases through the inner lining of the mouth, announced today that it has created a scientific advisory board in an effort to further its drug development programs, specifically in the areas of oncology and metabolic diseases
-
Cypress Bioscience Announces Agreement To Discontinue Co-Promotion Of Savella With Forest Laboratories
8/5/2010
Cypress Bioscience, Inc., a pharmaceutical company engaged in the development of innovative drugs to treat central nervous system disorders, today announced that it is discontinuing its rights under its agreement with Forest Laboratories to co-promote Savella®, its drug for fibromyalgia
-
Adoption Of In Silico Tools In Drug Discovery Accelerates Time To Market And Confers Cost Advantages, Notes Frost & Sullivan
8/5/2010
Due to the decrease in the rollout of blockbuster drugs in recent years, the focus has intensified on the development of in silico screening systems. There is greater emphasis on reducing the cycle time significantly to shorten the time to market for new drugs
-
New Earth BioMed Launches Natural-Product-Based Cancer Drug Discovery Program
8/5/2010
New Earth BioMed, a new 501(c)3 nonprofit corporation, has launched a long-term drug discovery program to identify mixtures of nontoxic plant compounds useful in treating cancer. An estimated 77 percent of approved cancer and anti-infective drugs in the United States are either natural products or are derived from them
-
Five Prime Therapeutics, Inc. Announces Strategic Alliance With GlaxoSmithKline To Discover Innovative Biologics For Skeletal Muscle Disorders
8/3/2010
Five Prime Therapeutics, Inc. (FivePrime), a leader in the discovery and development of innovative biologics announced today that it has formed a focused strategic drug discovery alliance with GlaxoSmithKline. This new collaboration gives GSK exclusive access to FivePrime's drug discovery platforms specifically in the areas of sarcopenia, cachexia and other skeletal muscle disorders. Under the terms of the agreement, GSK will receive access to FivePrime's comprehensive proprietary collection of secreted proteins and transmembrane
